Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1950 2
1951 3
1952 5
1953 3
1954 2
1956 2
1957 3
1958 2
1959 5
1960 3
1961 1
1962 3
1963 2
1964 4
1965 5
1966 4
1967 4
1968 2
1969 5
1970 7
1971 4
1972 5
1973 3
1974 11
1975 10
1976 10
1977 9
1978 10
1979 11
1980 17
1981 21
1982 7
1983 10
1984 9
1985 4
1986 31
1987 27
1988 22
1989 22
1990 16
1991 17
1992 19
1993 11
1994 10
1995 4
1996 20
1997 12
1998 16
1999 14
2000 14
2001 3
2002 14
2003 11
2004 14
2005 13
2006 16
2007 16
2008 20
2009 22
2010 21
2011 20
2012 22
2013 18
2014 14
2015 24
2016 18
2017 39
2018 26
2019 18
2020 32
2021 26
2022 31
2023 15
2024 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

884 results

Results by year

Filters applied: . Clear all
Page 1
Pathogenic or benign?
Du PP, Liu K, Bassik MC, Hess GT. Du PP, et al. Among authors: hess gt. Nat Biotechnol. 2022 Jun;40(6):834-836. doi: 10.1038/s41587-022-01333-y. Nat Biotechnol. 2022. PMID: 35578021 No abstract available.
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Liebers N, et al. Among authors: hess g. Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. Blood Adv. 2021. PMID: 34196677 Free PMC article.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Among authors: hess g. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jiménez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Siddiqi R, Reitan J, Wade S, Salles G. Hess G, et al. Br J Haematol. 2023 Aug;202(4):749-759. doi: 10.1111/bjh.18519. Epub 2022 Oct 18. Br J Haematol. 2023. PMID: 36257914 Free PMC article.
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. O'Connor OA, et al. Among authors: hess g. J Clin Oncol. 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22. J Clin Oncol. 2015. PMID: 26101246 Free PMC article. Clinical Trial.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, Kim WS, Hess G, El-Sharkawi D, Diefenbach CS, Huang H, To I, Parreira J, Wu M, Kwan A, Assouline S. Matasar M, et al. Among authors: hess g. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):240-253. doi: 10.1016/j.clml.2023.12.005. Epub 2023 Dec 12. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38195322 Free article. Clinical Trial.
Translation readthrough mitigation.
Arribere JA, Cenik ES, Jain N, Hess GT, Lee CH, Bassik MC, Fire AZ. Arribere JA, et al. Among authors: hess gt. Nature. 2016 Jun 30;534(7609):719-23. doi: 10.1038/nature18308. Epub 2016 Jun 1. Nature. 2016. PMID: 27281202 Free PMC article.
884 results